Overdose and COVID-19 in Baja California, Mexico: The Need for New Methodologies for Understanding Local Trends

Throughout North America, the illicit drug supply's shift to illicitly manufactured fentanyl (IMF) has fueled a multiwave overdose crisis.1 In response to the public health crisis, several jurisdictions in the United States and Canada adopted a range of harm reduction strategies. These strategi...

Full description

Saved in:
Bibliographic Details
Published in:American journal of public health (1971) 2024-06, Vol.114 (6), p.590-592
Main Authors: Lira, Jaime Arredondo Sanchez, Goodman-Meza, David
Format: Article
Language:English
Subjects:
Alcohol
Cities
Cocaine
Collaboration
Correspondence
COVID-19
COVID-19 - epidemiology
Crises
Drug abuse
Drug addiction
Drug overdose
Drug Overdose - epidemiology
Drug policy
Drug use
Drugs
Fentanyl
Harm reduction
Humans
Mental health
Mexico - epidemiology
Mortality
Naloxone
Narcotics
Opioids
Overdose
Pandemics
Public health
SARS-CoV-2
Trends
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Throughout North America, the illicit drug supply's shift to illicitly manufactured fentanyl (IMF) has fueled a multiwave overdose crisis.1 In response to the public health crisis, several jurisdictions in the United States and Canada adopted a range of harm reduction strategies. These strategies include take-home naloxone programs, community drug checking services, increased access to medications for opioid use disorder, and the prescription of safe supply medications.In Mexico, the implementation of harm reduction interventions has been extremely limited2 Faced with opposition at various government levels, local harm reduction programs have struggled to emerge or operate at full scale. Meanwhile, certain Mexican border areas are experiencing a rapid emergence of IMF in their local drug supply,3 leading to a spike in overdoses and an increase in other negative health outcomes for people who use drugs.
ISSN:0090-0036
1541-0048
1541-0048
DOI:10.2105/AJPH.2024.307672